Evaluation and Management of Non-Functional Neuroendocrine Tumors for Metastasis
For non-functional neuroendocrine tumors, you must obtain multimodal imaging with CT/MRI plus somatostatin receptor imaging (68Ga-DOTATATE PET/CT preferred), measure plasma chromogranin A, perform TNM staging, and determine Ki-67 proliferation index to guide treatment decisions—with surgery as first-line for resectable disease and systemic therapy selection based on tumor grade, somatostatin receptor status, and disease burden for advanced cases.
Initial Diagnostic Workup
Biochemical Testing
- Plasma chromogranin A (pCgA) is the essential general NET marker 1
- For non-functioning pancreatic NETs, pCgA and pancreatic polypeptide (PP) are typically elevated 1
- Plasma NSE may be valuable for poorly differentiated G3 tumors when pCgA is normal 1
- Exclude functional syndromes even in "non-functioning" tumors, as they may secrete hormones without clinical syndrome 1
Imaging for Staging
Primary tumor detection requires a multimodality approach 2:
CT or MRI (multiphasic with IV contrast) as the baseline anatomical imaging 1, 3
MRI is preferred for liver and pancreatic evaluation in initial staging 3
Somatostatin receptor imaging is critical:
For metastasis detection, somatostatin receptor imaging is the most sensitive modality 2
Additional modalities as needed: endoscopic ultrasound (EUS), PET with 18F-DOPA or 11C-5HTP 1
Pathological Assessment
Critical pathology elements to report 3:
- Morphology and differentiation (well-differentiated NET vs poorly differentiated NEC)
- Grading by Ki-67 proliferation index and mitotic count:
- G1: Ki-67 ≤2%
- G2: Ki-67 3-20%
- G3: Ki-67 >20%
- Immunohistochemistry: chromogranin A and synaptophysin 3
- SSTR staining is optional but helpful for treatment planning 3
TNM Staging
Apply the ENETS/UICC TNM classification system 1, 3:
- Assess T stage (tumor size and local invasion)
- N stage (regional lymph node involvement)
- M stage (distant metastases)
Common pitfall: Tumors ≤2 cm can still harbor malignant potential—24% of non-functional pancreatic NETs ≤2 cm are carcinomas, and lymph node metastases occur in tumors as small as 1.2 cm 6.
Treatment Algorithm Based on Disease Stage
Localized/Locoregional Disease (No Distant Metastases)
Tumor size is a critical decision point for non-functional pancreatic NETs:
Tumors 11-15 mm: Observation may be considered but surgery improves outcomes 7, 8
- Risk of metastases increases significantly above 15 mm 8
Tumors >15-20 mm: Surgical resection is recommended 7, 6, 8
- Curative surgery should be performed for control of primary tumor 6
- Lymph node dissection is recommended for tumors ≥2.5 cm 6
- At minimum, lymph node sampling for tumors ≥1 cm 6
- For pancreatic head tumors: pancreatoduodenectomy with peripancreatic lymph node dissection 10
- For body/tail tumors: distal pancreatectomy with splenectomy and lymph node dissection 10
All patients with small intestinal NETs should be evaluated for curative surgery in an interdisciplinary setting 1.
Advanced/Metastatic Disease
First-line therapy selection depends on multiple factors 5:
For G1-G2 NETs with Ki-67 <10%, sstr-positive, asymptomatic, low tumor burden:
- Somatostatin analogs (octreotide or lanreotide) are first-line 5
- Alternative: "Watch and wait" approach is acceptable per NCCN/NANETS guidelines 5
For G1-G2 NETs with Ki-67 10-20%, or symptomatic/high tumor burden:
- Chemotherapy (CAP-TEM or 5FU-STZ) is recommended first-line 5
- Molecular targeted agents (everolimus or sunitinib) are alternatives for sstr-negative tumors 5
For G3 NETs (Ki-67 >20%):
- Chemotherapy regimens are primary treatment 5
- Selected G3 NETs with Ki-67 <55%, no symptoms, low burden may be observed 5
Second-Line and Beyond
After SSA failure in sstr-positive G1-G2 tumors 5:
- Category 1 options: Everolimus or sunitinib 5, 4
- PRRT with 177Lu-DOTATATE for sstr-positive tumors (Category 1 for midgut tumors) 5, 4
- Chemotherapy (CAP-TEM) if goal is symptom reduction or tumor burden reduction 5
Sequencing considerations 5:
- For Ki-67 <10%: SSA → chemotherapy or MTAs → PRRT as third-line
- For Ki-67 10-20%: chemotherapy → MTAs → PRRT as third-line
- ENETS positions PRRT as second-line, with chemotherapy or MTAs as subsequent options 5
Liver-Predominant Metastatic Disease
Hepatic-directed therapies 2, 4:
- Arterial embolization
- Hepatic chemoembolization
- Hepatic radioembolization (Category 2B)
- Cytoreductive surgery/ablative therapy (Category 2B) for select patients
Surgical resection of liver metastases should be considered when:
- Limited hepatic disease with resectable primary 10
- G1/G2 NET with type I liver metastases (limited number) 11
- Cytoreductive surgery for type II liver metastases (multiple but resectable) in highly selected patients meeting specific criteria 11
- Avoid surgery for type III liver metastases (diffuse) or NEC with liver metastases 11
Key Clinical Pitfalls
Don't assume all small tumors are benign: 24% of non-functional pancreatic NETs ≤2 cm are carcinomas 6
Somatostatin receptor status is not optional: This determines eligibility for SSAs and PRRT, which are major treatment modalities 5
Ki-67 proliferation index drives treatment decisions: The distinction between <10%, 10-20%, and >20% fundamentally changes therapeutic approach 5
Chromogranin A can be normal in G3 tumors: Use NSE as alternative marker 1
Genetic syndromes must be excluded: Evaluate for MEN1 and obtain family history in all NET patients 2
Cholecystectomy should be considered during abdominal surgery if long-term somatostatin analog treatment is anticipated 2